

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
06 January 2022 (06.01.2022)



(10) International Publication Number  
**WO 2022/003357 A1**

(51) International Patent Classification:

C12N 15/86 (2006.01) A61P 13/12 (2006.01)  
A61P 37/00 (2006.01)

(21) International Application Number:

PCT/GB2021/051668

(22) International Filing Date:

30 June 2021 (30.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2010009.5 30 June 2020 (30.06.2020) GB

(71) Applicants: SYNCONA INVESTMENT MANAGEMENT LIMITED [GB/GB]; 8 Bloomsbury St, 2nd Floor, London WC1B 3SR (GB). THE UNIVERSITY OF BRISTOL [GB/GB]; Beacon House, Queens Road, Bristol BS8 1QU (GB). PURESPRING THERAPEUTICS LIMITED [GB/GB]; 8 Bloomsbury Street, 2nd Floor, London WC1B 3SR (GB).

(72) Inventors: GRIFFITH, Alan William; Purespring Therapeutics Limited, 8 Bloomsbury St, 2nd Floor, London WC1B 3SR (GB). STANCZUK, Lukas; Purespring Therapeutics Limited, 8 Bloomsbury St, 2nd Floor, London WC1B 3SR (GB). KUZMUK, Valeryia; Purespring Therapeutics Limited, 8 Bloomsbury St, 2nd Floor, London WC1B 3SR (GB). HOLLOWOOD, Chris; Syncona Investment Management Limited, 8 Bloomsbury St, 2nd Floor, London WC1B 3SR (GB). SCHMIDT, Dominic; Syncona Investment Management Limited, 8 Bloomsbury St, 2nd Floor, London WC1B 3SR (GB). SALEEM-UD-DIN, Moin Ahson; The University of Bristol, Beacon House, Queens Road, Bristol BS8 1QU (GB). WELSH, Gavin Iain; The University of Bristol, Beacon House, Queens Road, Bristol BS8 1QU (GB).

(74) Agent: D YOUNG & CO LLP; 120 Holborn, London EC1N 2DY (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: VECTOR

(57) Abstract: The present invention provides a viral vector comprising a nucleotide sequence encoding a complement protein, wherein the nucleotide sequence is operably linked to a podocyte-specific promoter and/or the viral vector is capable of specifically transducing podocytes.

WO 2022/003357 A1